Detalhes do Documento

Comparative Effectiveness of COVID-19 Vaccines in Preventing Infections and Disease Progression from SARS-CoV-2 Omicron BA.5 and BA.2, Portugal

Autor(es): Kislaya, Irina ; Casaca, Pedro ; Borges, Vítor ; Sousa, Carlos ; Ferreira, Bibiana I. ; Fonte, Ana ; Fernandes, Eugénia ; Dias, Carlos Matias ; Duarte, Sílvia ; Almeida, José Pedro ; Grenho, Inês ; Coelho, Luís ; Ferreira, Rita ; Ferreira, Patrícia Pita ; Borges, Cláudia Medeiros ; Isidro, Joana ; Pinto, Miguel ; Menezes, Luís ; Sobral, Daniel ; Nunes, Alexandra ; Santos, Daniela ; Gonçalves, António Maia ; Vieira, Luís ; Gomes, João Paulo ; Leite, Pedro Pinto ; Nunes, Baltazar ; Machado, Ausenda ; Peralta-Santos, André

Data: 2023

Identificador Persistente: http://hdl.handle.net/10400.18/8950

Origem: Repositório Científico do Instituto Nacional de Saúde

Assunto(s): BA.2; BA.5; COVID-19; Omicron; SARS-CoV-2; Coronavirus Disease; Death; Hospitalization; Postinfection Vaccine Effectiveness; Respiratory Infections; Severe Acute Respiratory Syndrome Coronavirus 2; Vaccine-preventable Diseases; Viruses; Portugal; Infecções Respiratórias; Doenças Evitáveis pela Vacinação; Determinantes da Saúde e da Doença


Descrição

We estimated comparative primary and booster vaccine effectiveness (VE) of SARS-CoV-2 Omicron BA.5 and BA.2 lineages against infection and disease progression. During April-June 2022, we implemented a case-case and cohort study and classified lineages using whole-genome sequencing or spike gene target failure. For the case-case study, we estimated the adjusted odds ratios (aORs) of vaccination using a logistic regression. For the cohort study, we estimated VE against disease progression using a penalized logistic regression. We observed no reduced VE for primary (aOR 1.07 [95% CI 0.93-1.23]) or booster (aOR 0.96 [95% CI 0.84-1.09]) vaccination against BA.5 infection. Among BA.5 case-patients, booster VE against progression to hospitalization was lower than that among BA.2 case-patients (VE 77% [95% CI 49%-90%] vs. VE 93% [95% CI 86%-97%]). Although booster vaccination is less effective against BA.5 than against BA.2, it offers substantial protection against progression from BA.5 infection to severe disease.

Tipo de Documento Artigo científico
Idioma Inglês
Contribuidor(es) Repositório Científico do Instituto Nacional de Saúde
Licença CC
facebook logo  linkedin logo  twitter logo 
mendeley logo

Documentos Relacionados

Não existem documentos relacionados.